Business Wire

YOKOGAWA-ELECTRIC

7.4.2020 09:02:09 CEST | Business Wire | Press release

Share
Yokogawa Releases AI-enabled Versions of SMARTDAC+ Paperless Recorders and Data Logging Software, and Environmentally Robust AI-enabled e-RT3 Plus Edge Computing Platform for Industry Applications

Yokogawa Electric Corporation (TOKYO: 6841) announces the release of artificial intelligence (AI)-enabled versions of the GX series panel-mount type paperless recorders, GP series portable paperless recorders, and GA10 data logging software, which are components of the highly operable and expandable SMARTDAC+TM data acquisition and control system. This new AI functionality includes the future pen, a function developed by Yokogawa that enables the drawing of predicted waveforms. Yokogawa is also releasing a new CPU module for the e-RT3TM Plus edge computing platform that is environmentally robust and PythonTM*1  compatible. The GX/GP and e-RT3 Plus release is set for April 8, and the GA10 software will be released on May 13. The SMARTDAC+ system is a product in the OpreXTM Data Acquisition family, and the e-RT3 Plus is part of the OpreX Control Devices family.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200407005269/en/

The introduction of AI functions such as the future pen, a first for industrial recorders*2 , will help users identify and correct problems before they have a chance to cause disruptions in production operations.

Background

There is a rising interest in the manufacturing sector in the use of AI to prevent equipment malfunctions and maximize productivity. At the same time, AI technologies have a steep learning curve, and the introduction of existing AI-enabled products and the analysis of their data is typically beyond the expertise of novices to this field.

Recorders are used in manufacturing and R&D to acquire, display, and record data on voltage, current, temperature, flow rate, pressure, and other process variables. Yokogawa is a leading manufacturer of recorders, and also holds a solid track record in the consulting industry with the use of machine learning to predict and analyze both equipment anomalies and product quality for manufacturers. To improve productivity and product quality, Yokogawa is now building user-friendly AI-related functions into its recorders, data logging software, and controllers. For example, these functions now enable GX/GP series recorders to draw waveforms on screen that are predicted based on the real-time analysis of collected data so that users can anticipate and correct problems early on, before they have a chance to escalate. Also, the e-RT3 Plus edge computing platform has been enhanced with the addition of support for Python, a programming language that is widely used in AI R&D.

Enhancements

  1. AI future pen function for drawing of predicted waveforms
    A future pen function has been added to the GX/GP series recorders to enable the drawing of predicted waveforms based on the use of AI to analyze collected data in real time. By viewing predicted waveforms up to a specified time point, users can identify the likelihood that an alarm will occur and take action in advance. An industry first, this adds an entirely new dimension to the capabilities of recorders, whose collection and recording of data has conventionally been used to visualize the past and present performance of various types of equipment.

  2. Detection of anomalies and prediction of potential failures
    A machine learning function has been added to the GA10 data logging software that can acquire normal process values from correctly operating devices and use these values to detect an anomaly and predict a potential failure, a capability that up till now has only been possessed by the most expert operators. Data on which device is expected to fail is displayed on screen, highlighted within a yellow frame. Maintenance can thus be performed before the device fails, minimizing the likelihood of any disruptions to production. This function does not necessitate the collection of abnormal process values and thus is easy to implement.

  3. Addition of Python support
    e-RT3 Plus controllers can be built into various types of devices. For use with these controllers, Yokogawa is releasing a new CPU module that supports Python, a programming language that is widely used in machine learning and other branches of the AI field. The large library of software written in this language includes numerous tools that programmers can use to speed up their development of AI predictive diagnostic functions. This new CPU module also has excellent environmental resistance, and easily accommodates existing input/output (IO) modules. The addition of this new module to the e-RT3 Plus edge computing platform will enable the introduction of AI solutions in a wider range of industries.

For added flexibility, the new e-RT3 Plus controllers run on Linux Ubuntu*3 , a general-purpose operating system.

Major Target Markets
GX series: Production sites in a wide range of industries including iron and steel, electric power, chemicals, pulp and paper, foods, pharmaceuticals, heat treatment equipment, water supply and wastewater treatment, electrical equipment, and electronics
GP series: Companies engaged in R&D of home appliances, automobiles, semiconductors, and new-energy related technologies as well as academic institutions and research institutes
GA10: Both of the above
e-RT3 Plus: Manufacturers of industrial machinery and companies engaged in the assembly of electronic components and devices

Applications
Monitoring and recording of voltage, current, temperature, flow rate, pressure, and other process variables; evaluation of performance in equipment management, production, and product development; safety and reliability evaluation during product quality inspection processes

*1 A versatile programming language that is widely used in AI application development. Designed to be user-friendly with simple code, Python enables users to write various programs in a clear manner with fewer lines of code than other languages. In addition, numerous Python open-source libraries are available for use in machine learning and other AI applications.
*2 Based on a March 2020 Yokogawa survey
*3 A Linux distribution and installation package provided by Canonical Ltd., a UK-based software company

About SMARTDAC+
SMARTDAC+ stands for smart data acquisition and control, and the SMARTDAC+ system includes a variety of IO modules and options. With the product lineup of the GX series panel-mount type paperless recorders, GP series portable paperless recorders, GA10 data logging software, and GM series data acquisition systems, SMARTDAC+ offers extensive support for manufacturing process monitoring and performance evaluation.

For more information
https://www.yokogawa.com/ai-products/

About OpreX
OpreX is the comprehensive brand for Yokogawa's industrial automation (IA) and control business. The OpreX name stands for excellence in the technologies and solutions that Yokogawa cultivates through the co-creation of value with its customers, and encompasses the entire range of Yokogawa's IA products, services, and solutions. This brand comprises the following five categories: OpreX Transformation, OpreX Control, OpreX Measurement, OpreX Execution, and OpreX Lifecycle. The SMARTDAC+ data acquisition and control system is part of the OpreX Data Acquisition lineup, which is aligned under the OpreX Measurement category. The OpreX Measurement category includes field equipment and systems for highly precise measurement, data collection, and analysis.

With this brand, Yokogawa will deliver integrated solutions that address specific needs and support its customers in their efforts to transform and grow their businesses.

About Yokogawa
Founded in 1915, Yokogawa engages in broad-ranging activities in the areas of measurement, control, and information. The industrial automation business provides vital products, services, and solutions to a diverse range of process industries including oil, chemicals, natural gas, power, iron and steel, and pulp and paper. With the life innovation business, the company aims to radically improve productivity across the pharmaceutical and food industry value chains. The test & measurement, aviation, and other businesses continue to provide essential instruments and equipment with industry-leading precision and reliability. Yokogawa co-innovates with its customers through a global network of 113 companies spanning 60 countries, generating US$3.6 billion in sales in FY2018. For more information, please visit www.yokogawa.com .

The names of corporations, organizations, products, services and logos herein are either registered trademarks or trademarks of Yokogawa Electric Corporation or their respective holders.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye